rss.nicho

1K posts

rss.nicho banner
rss.nicho

rss.nicho

@GiadaNicholas

disclaimer: tweets are my own opinions & should not be seen as any investment advice Corporate-finance & stocks (sp) are associated with risks & uncertainties

Katılım Haziran 2014
33 Takip Edilen975 Takipçiler
Sabitlenmiş Tweet
rss.nicho
rss.nicho@GiadaNicholas·
$ABCL AbCellera – a true diamond I love technical analysis. I’ve spent years mastering indicators, reading charts, recognizing patterns. But no matter how precise it is, technicals will always come second to instinct. When I first found AbCellera ($ABCL), I was just curious. I didn’t invest a cent—not until I started digging deeper. I discovered Carl Hansen, the CEO. A brilliant scientist with unmatched passion. He once spent a week in Dr. James’ lab and completed more experiments than their best student would in a year, creating Fluidigm’s first commercial product. Carl isn’t just running a company—he’s building a legacy. AbCellera’s silence on social media frustrated me at first. But after a year of watching, I get it. They don’t talk. They execute. I kept digging. They helped DARPA deliver a COVID antibody, partnered with Lilly, secured Canadian government funding, built state-of-the-art facilities, amassed huge cash reserves, and filed unique microfluidics patents (recently defended successfully in court). Their GMP manufacturing site goes live this year. How many biotechs can say the same? Then I looked at the chart. From $60 to $2. The market punished them for lack of revenue, not realizing they were quietly transforming into a company that could rival Big Pharma. As an entrepreneur, I get it. My first store thrived, then struggled. I reinvested, expanded, and now I’m in a place I never imagined. AbCellera is doing the same. They’ve been underestimated because few realized how much they were restructuring to achieve 100x what they did when shares were $40. Insiders buying at $2.16 and $3.24 shows confidence from those who know more than any of us. Institutions went from 40% to 60% ownership in months. I’m no institution. I’m just a retail investor who went all-in on Carl Hansen. And yes, I once dreamt of Carl. At $2 he smiled and said, “Great things are coming.” That’s the Carl I feel in my gut. My all-in bet will pay off. AbCellera isn’t a meme stock. It’s not a penny stock. It’s a biotech titan in the making. I’m already smiling at the thought of $20… $30… $40.
rss.nicho tweet media
English
3
11
152
11.7K
rss.nicho
rss.nicho@GiadaNicholas·
$ABCL Top Holders don’t sell. Baker Bros Advisor Avg price 21$ In 2026 $ABCL will hits 30$ Today maybe spike at 7$ for gamma squeeze and shorts covering. 👀 Watch closely. Not financial advice.
rss.nicho tweet media
English
4
10
118
11.1K
Alex
Alex@ehhope3·
@GiadaNicholas Definitely not financial advice, keep dreaming 😂
English
1
0
4
497
진 한
진 한@ftczzjf6ty·
@GiadaNicholas I have been waiting for your writing. I always follow it closely.
English
1
0
5
757
rss.nicho
rss.nicho@GiadaNicholas·
Just my personal opinion, not financial advise. Tomorrow $ABCL hit 7$, or try to hit 7$
English
12
0
106
7.5K
vaiL
vaiL@Moleavv·
@GiadaNicholas It definitely will hit $7 in the short term, what makes you think tomorrow is the day, is it based off the chart?
English
1
0
0
285
Jim Roslund
Jim Roslund@RoslundJim·
Something is happening with $ABCL Up 28% in the last month. Q2: revenue +133% YoY, $750M cash, major pipeline progress. Volume is surging. Closing in on the $5 trigger with ~13.6% short interest. A clean break could force shorts to cover fast.
English
1
1
10
719
rss.nicho
rss.nicho@GiadaNicholas·
I swear I can't believe it, I'm honestly a bit shocked. $ABCL
English
13
1
48
5.2K
rss.nicho
rss.nicho@GiadaNicholas·
$ABCL gap filled.
English
9
1
36
3.2K